This study involves people with Primary Sjogren’s Disease, a condition where the body’s immune system attacks its own moisture-producing glands, leading to dryness of the eyes and mouth, as well as other symptoms throughout the body. The disease can also affect other organs and cause fatigue and joint pain. The study will test a medication called IMVT-1402, which is given as an injection under the skin, and compare it to placebo. The purpose of this study is to find out how well IMVT-1402 works in reducing the activity of the disease in people who have moderate to severe symptoms affecting various parts of the body.

The study will look at whether IMVT-1402 can help improve the overall disease activity by measuring changes in a scoring system that tracks how different body systems are affected by the disease. Participants will receive either IMVT-1402 or placebo through injections under the skin once a week. The main part of the study will last for 24 weeks, during which doctors will monitor how the disease activity changes from the beginning of the study. The total treatment period can last up to 48 weeks.

People taking part in this study will need to have been diagnosed with Primary Sjogren’s Disease for at least 12 months and have a certain level of disease activity affecting their body systems. They will also need to have specific antibodies in their blood that are commonly found in people with this condition, and they must still have some ability to produce saliva. Throughout the study, participants will have regular visits to check their symptoms and how well the treatment is working.